ONCOLOGY Nurse Edition October 2008, Vol 22 No 11

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Jacob Sands, MD

August 4th 2025

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The FDA has accepted a new drug application for the prostate-specific membrane antigen PET imaging agent.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

August 6th 2025

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Related Content

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Jacob Sands, MD

August 4th 2025

FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

The new formulation should increase the batch size by approximately 50% and will offer the potential to expand access to patients in new geographic locations.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

July 31st 2025

Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.